ArticleJournal of the American Board of Family Medicine : JABFM
Clinicians' Perspectives on Barriers and Enablers of Optimal Prescribing in Patients with Dementia and Coexisting Conditions.
Article in Journal of the American Board of Family Medicine : JABFM. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06335953 (Demonstration of ALIGN), which is not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Demonstration of ALIGN: Aligning Medications With What Matters Most
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- The views of healthcare professionals and family members on deprescribing preventive medication in people living with dementia: a qualitative systematic review.BMC geriatrics · 2026Pooled it
- Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review.BMJ open · 2022Pooled it
- Pharmacist-led telehealth deprescribing for people living with dementia and polypharmacy in primary care: A pilot study.Journal of the American Geriatrics Society · 2024Trial
- Ethical Aspects of Physician Decision-Making for Deprescribing Among Older Adults With Dementia.JAMA network open · 2023Trial
- Stakeholder Perspectives on Identifying and Managing Comorbid Health Conditions Among Nursing Home Residents with Dementia: A UK Single-Site Qualitative Study.Healthcare (Basel, Switzerland) · 2026Article
- Patterns and Trends of Glucose-Lowering Therapy in Alzheimer's Disease and Related Dementias.Diabetes, obesity & metabolism · 2026Article
- Developing a Novel Digital Tool for Personalised Antipsychotic Prescribing in People Living With Dementia: The Views of Australian Clinicians.Dementia (London, England) · 2026Article
- Nurse Practitioners' Experiences Navigating Treatment Decision-Making Affecting Older People with Neurocognitive Disorders and Cancer.The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres · 2026Article
- Access of medication review for people living with dementia: An analysis of inequality using Swedish register data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Associations between falls and other serious adverse events and antihypertensive medication in individuals with dementia: An observational cohort study.PLoS medicine · 2025Observational
- Multimorbidity in dementia: Current perspectives and future challenges.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Characterizing patient portal use of people with cognitive impairment and potentially inappropriate medications.Journal of the American Geriatrics Society · 2025Article
- Behavioural analysis of factors influencing prescribing for neurodegenerative diseases: A rapid review.PloS one · 2025Review
- Use of the Patient Portal to Discuss Medications Among People with Dementia and Their Care Partners.Journal of general internal medicine · 2024Article
- eConsultation for Deprescribing Among Older Adults: Clinician Perspectives on Implementation Barriers and Facilitators.Journal of general internal medicine · 2024Article
- Deprescribing for people living with dementia: ALIGNing interventions and outcomes.Journal of the American Geriatrics Society · 2024Article
- Healthcare professionals' experiences with the use of antipsychotics in dementia.Exploratory research in clinical and social pharmacy · 2024Article
- Carers' experiences and perspectives of the use of anticholinergic medications in people living with dementia: Analysis of an online discussion forum.Health expectations : an international journal of public participation in health care and health policy · 2024Article
- A need to integrate pharmacological management for multimorbidity into dementia guidelines in Australia.Frontiers in public health · 2024Review
- Antipsychotic use among older patients with dementia receiving home health care services: Prevalence, predictors, and outcomes.Journal of the American Geriatrics Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
purposePatients with dementia experience high rates of polypharmacy, potentially inappropriate medication use, and adverse drug events. There is little guidance for clinicians on how to optimize prescribing for this population. Our objective was to investigate clinician-perceived barriers to and facilitators of optimizing prescribing for people with dementia.
methodsQualitative study involving semistructured interviews of primary care and specialist clinicians in urban, suburban, and rural settings. Transcripts were analyzed using qualitative content analysis.
resultsInterviews were conducted with 12 primary care and 9 specialist clinicians, with a mean (SD) age of 47 (9) and mean (SD) of 14 (10) years in practice. Clinicians cited decisions regarding the following drug classes as particularly challenging: oral anticoagulants, antidiabetic agents, statins, bladder antimuscarinics, and antipsychotics. Perceived enablers of optimizing prescribing included access to interdisciplinary services and guidelines for nondementia illnesses (eg, diabetes) addressing the care of people with dementia. Barriers included the lack of data on efficacy and safety of most medications in people with dementia, difficulty assessing medication effects in an individual patient, and the perception that stopping medications is seen as "giving up." Clinicians used a variety of strategies to discuss risks and benefits of medications with patients and caregivers.
conclusionsClinicians identified numerous barriers to and some facilitators of optimizing prescribing in people with dementia. More data are needed on the benefits and harms of stopping medications in this population. Research should also test different approaches for supporting informed decision making about medications by people with dementia and caregivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.